miR-1290 Is a Biomarker in DNA-Mismatch-Repair-Deficient Colon Cancer and Promotes Resistance to 5-Fluorouracil by Directly Targeting hMSH2

5-Fluorouracil (5FU)-based adjuvant therapy is the first-line therapy for treating stage II and III colon cancer after surgery. However, its therapeutic efficacy is limited because of chemoresistance, especially in deficient mismatch repair (dMMR) colon cancer. Here, we first used laser capture micr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Ling, Jiang, Tao, Shao, Huanzhang, Zhong, Lin, Wang, Zhaowen, Liu, Yuan, Tang, Huamei, Qin, Bingyu, Zhang, Xiaoqing, Fan, Junwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443909/
https://www.ncbi.nlm.nih.gov/pubmed/28624221
http://dx.doi.org/10.1016/j.omtn.2017.05.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443909/
https://www.ncbi.nlm.nih.gov/pubmed/28624221
http://dx.doi.org/10.1016/j.omtn.2017.05.006

Ejemplares similares